[XIII. Pharmacotherapy and clinical trials]

ABSTRACT

The novel coronavirus spread from China to the rest of the world, and a major pandemic has followed. In developing treatments for coronavirus disease 2019 (COVID-19), drug repositioning of existing drugs with antiviral activity has been the main focus, and s uppression of hyperimmunity is also a major theme in severe cases. Although the treatment for COVID-19 is still in its infancy, knowledge based on clinical and other studies is accumulating at an unprecedented rate.